Subsequent Malignancies After CD19|Targeted Chimeric Antigen ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma.

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving ...

Subsequent Malignancies after CD19-Targeted Chimeric Antigen ...

The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL.

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Subsequent Malignancies After CD19-Targeted Chimeric. Antigen Receptor T Cells in Patients With Lymphoma. Rachel Lorenc1,#, Roni Shouval1,2 ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

The aim of this study is to determine the incidence of subsequent malignancies in adult patients with B-NHL.

Subsequent malignant neoplasms in patients previously treated with ...

Chimeric antigen receptor (CAR) T-cell therapy is a novel therapy that uses either gamma-retroviral or lentiviral vectors to genetically modify a patient's ...

T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell ...

On 28 November 2023, the US Food and Drug Administration announced an investigation into the risk of T-cell malignancies after autologous chimeric antigen ...

Late Events after Treatment with CD19-Targeted Chimeric Antigen ...

Subsequent malignancies occurred in 15% of patients, including 5% with myelodysplastic syndrome (MDS). Among patients with ongoing CR and with no MDS, 16 ...

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products. Such cancers have included T- ...

FDA Investigating Serious Risk of T-cell Malignancy

FDA has received reports of T-cell malignancies, including chimeric antigen ... CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell ...

Secondary myeloid neoplasms after CD19 CAR T therapy ... - Frontiers

Background: Several chimeric antigen receptor T cells (CAR T) targeting CD19 have induced profound and prolonged remission for refractory/relapsed (R/R) B-cell ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Subsequent malignancies were grouped into 3 primary categories solid tumor, hematologic malignancy, and dermatologic malignancy with cumulative incidences at 36 ...

Long-term outcomes following CAR T cell therapy - Nature

Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells.

Subsequent Malignancies after CD19-Targeted Chimeric Antigen ...

Semantic Scholar extracted view of "Subsequent Malignancies after CD19-Targeted Chimeric Antigen Receptor T cells in Patients with Lymphoma.

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma ... To read the full-text of this research ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

In: Transplantation and Cellular Therapy. 2024. ... Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma. / ...

The Current Landscape of Secondary Malignancies after CAR T ...

Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in ...

Characterization of second primary malignancies post CAR T-cell ...

Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative approach in r/r HMs treatment, yielding significantly improved ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen ...

Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma ... Authors: Rachel Lorenc; Roni Shouval; Jessica R. Flynn ...

Donor-derived CD19-targeted chimeric antigen receptor T cells in ...

CD19-targeted chimeric antigen receptor (CAR) T cell therapy induces remission in the majority of patients with relapsed and refractory (r/r) B- ...